Show Notes
Is it really a good idea to get medical care from online pharmacies posing as clinics? This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor dig into a Yale secret shopper study that tested 49 websites selling GLP-1 medications online. The websites look and market like medical clinics, but the study found that most patients never spoke to a clinician at all before getting a prescription. Dr. Cooper, Mark, and Andrea unpack what real medical care requires, why these platforms skip it, and what that means for anyone considering this route. KEY TAKEAWAY Two-thirds of the sites in the study issued a prescription with no clinician contact of any kind — despite marketing themselves as medical clinics.
Fewer than 40% asked for any clinical measurement (blood pressure, labs, etc.), and only 18% asked whether the patient even had a primary care doctor.
Many of these sites are financially connected to compounding pharmacies and use leading questions to push add-ons that create untested drug combinations.
Real medical care means a full history, objective labs, and ongoing monitoring — not a five-minute questionnaire and an automatic credit card charge.
NOTABLE QUOTE "The marketing appears to be a medical clinic or a medical company, when in fact it's really just a sale of a drug." Dr. Emily Cooper LINKS & RESOURCES Study published in JAMA on the secret shopper findings Links & Resources Podcast Home: fatsciencepodcast.com Cooper Center for Metabolism: coopermetabolic.com Resources from Dr. Cooper: coopermetabolic.com/resources Join Our Community: patreon.com/cw/FatSciencePodcast Submit Your Question: [email protected] or [email protected] Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care. This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
More from Fat Science
Wondering why weight stalls on treatment? Dr. Emily Cooper explains how the brain defends set points and why eating less stops progress. Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener letters from around the world. The conversation addresses why athletic men with a BMI of 27 can still show high visceral fat on a DEXA scan, how medications defend metabolic set points, and why intentional undereating triggers starvation responses. The team also examines global access to metabolic treatments, dual incretin agonists versus single agonists, artificial sweeteners, and how to interpret two-hour insulin and glucose tolerance curves. Key Takeaways Rapid weight reduction without adequate nutrition can cause lean mass loss and trigger metabolic defense mechanisms. Dual incretin therapies stimulate GIP receptors far more than GLP-1 receptors compared to natural human hormones, creating different patient responses. Intentional calorie restriction reduces natural incretin production and can impair metabolic signaling, making mechanical fueling essential. Fasting insulin suppression combined with pre-diabetes indicators can reflect the brain pulling glucose during periods of low carbohydrate intake. Resources Mentioned Diabesity Foundations Course Cooper Center for Metabolism Diabesity Institute Connect with Us Podcast Home:fatsciencepodcast.com Cooper Center for Metabolism:coopermetabolic.com Diabesity Institute: diabesityinstitute.org Resources from Dr. Cooper:coopermetabolic.com/resources Join Our Community:patreon.com/cw/FatSciencePodcast Submit Your Question: [email protected] or [email protected] Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care. This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations. Produced by: Podcast Impact Studio https://podcastimpactstudio.com
What do new drug reports really mean for your treatment? Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues. KEY TAKEAWAYS Understanding the difference between efficacy estimand and treatment policy estimand.
Can metabolic dysfunction be the cause of anxiety?
What's the back-to-school metabolism shift all about?